Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;15(2):101–108. doi: 10.1111/j.1750-3639.2005.tb00504.x

Involvement of Clusterin and the Aggresome in Abnormal Protein Deposits in Myofibrillar Myopathies and Inclusion Body Myositis

I Ferrer 1,2,✉, M Carmona 1, R Blanco 1, D Moreno 1, B Torrejón‐Escribano 3, M Olivé 1
PMCID: PMC8095801  PMID: 15912881

Abstract

Myofibrillar myopathies (MM) are characterized morphologically by the presence of non‐hyaline structures corresponding to foci of dissolution of myofibrils, and hyaline lesions composed of aggregates of compacted and degraded myofibrillar elements. Inclusion body myositis (IBM) is characterized by the presence of rimmed vacuoles, eosinophilic inclusions in the cytoplasm, rare intranuclear inclusions, and by the accumulation of several abnormal proteins. Recent studies have demonstrated impaired proteasomal expression and activity in MM and IBM, thus accounting, in part, for the abnormal protein accumulation in these diseases. The present study examines other factors involved in protein aggregation in MM and IBM. Clusterin is a multiple‐function protein which participates in Aβ‐amyloid, PrPres and α‐synuclein aggregation in Alzheimer disease, prionopathies and α‐synucleinopathies, respectively. γ‐Tubulin is present in the centrosome and is an intracellular marker of the aggresome. Moderate or strong clusterin immunoreactivity has been found in association with abnormal protein deposits, as revealed by immunohistochemistry, single and double‐labeling immunofluorescence and confocal microscopy, in MM and IBM, and in target structures in denervation atrophy. γ‐Tubulin has also been observed in association with abnormal protein deposits in MM, IBM, and in target fibers in denervation atrophy. These morphological findings are accompanied by increased expression of clusterin and γ‐tubulin in muscle homogenates of MM and IBM cases, as revealed by gel electrophoresis and Western blots. Together, these observations demonstrate involvement of clusterin in protein aggregates, and increased expression of aggresome markers in association with abnormal protein inclusions in MM and IBM and in targets, as crucial events related with the pathogenesis of abnormal protein accumulation and degradation in these muscular diseases.

Full Text

The Full Text of this article is available as a PDF (389.5 KB).

References

  • 1. Ardley HC, Scott GB, Rose SA, Tan NGS, Robinson PA (2004) UCHL‐1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 90:379–391. [DOI] [PubMed] [Google Scholar]
  • 2. Askanas V, Engel WK (2001) Inclusion‐body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuro-pathol Exp Neurol 60:1–14. [DOI] [PubMed] [Google Scholar]
  • 3. Bugiani O, Giaccone G, Frigerio L, Farlow MR, Ghetti B, Tagliavini F (1994) Apolipoprotein E and J immunoreactivity in Gerstmann‐Sträussler‐Scheinker disease. Neurobiol Aging 15: S–156–S157. [Google Scholar]
  • 4. Chávez‐Zobel AT, Loranger A, Marceau N, Theriault JR, Lambert H, Landry J (2003) Distinct chaperone mechanisms can delay the formation of aggresomes by the myopathy‐causing R 120G αB‐crystallin mutant. Hum Mol Genet 12:1609–1620. [DOI] [PubMed] [Google Scholar]
  • 5. Choi‐Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M (1992) SP‐40,40 is a constituent of Alzheimer's amyloid. Acta Neuro-pathol 83:260–264. [DOI] [PubMed] [Google Scholar]
  • 6. Crowther DC (2002) Familial conformational diseases and dementias. Hum Mut 20:1–14. [DOI] [PubMed] [Google Scholar]
  • 7. Dagvadorj A, Olive M, Urtizberea JA, Halle M, Shantunov A, Bonnemann C, Park KY, Goebel HH, Ferrer I, Vicart P, Dalakas MC, Goldfarb LG (2004) A series of West European patients with severe cardiac and skeletal myopathy associated with a de novo R406W mutation in desmin. J Neurol 251:143–149. [DOI] [PubMed] [Google Scholar]
  • 8. Dalakas MC, Park K‐Y, Semino‐Mora C, Lee HS, Sivakumar K, Goldfarb LG (2000) Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 342:770–780. [DOI] [PubMed] [Google Scholar]
  • 9. De Bleecker JL, Engel AG, Ertl B (1996) Myofibrillar myopathy with foci of desmin positivity II. Immunocytochemical analysis reveals accumulation of multiple other proteins. J Neuropathol Exp Neurol 55:563–577. [DOI] [PubMed] [Google Scholar]
  • 10. DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, Paul SM, Aronow BJ, Holtzman DM (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. PNAS 99:10843–10848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Ferrer I, Martín B, Castaño JG, Lucas JJ, Moreno D, Olivé M (2004) Proteasomal expression and activity, and induction of the immunoprotesome in myofibrilar myopathies and inclusion body myositis. J Neuropathol Exp Neurol 63:484–498. [DOI] [PubMed] [Google Scholar]
  • 12. Fortun J, Dunn WA, Joy S, Li J, Notterpek L (2003) Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci 23:10672–10680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Fratta P, Engel WK, Askanas V (2003) Novel identification of aggresomes in sporadic inclusion body myositis (s‐IBM) muscle fibres suggests that inhibition of 26S/20S proteasome and misfolded proteins play a pathogenic role. Ann Neurol 54:845. [Google Scholar]
  • 14. Fratta P, Engel WK, Van Leeuwen FM, Hol EM, Vattemi G, Askanas V (2004) Mutant ubiquitin UBB′1 isaccumulated in sporadic inclusion‐body myositis muscle fibers. Neurology 63:1114–1117. [DOI] [PubMed] [Google Scholar]
  • 15. Freixes M, Puig B, Rodríguez A, Torrejón‐Escribano B, Blanco R, Ferrer I (2004) Clusterin solubility and aggregation in Creutzfeldt‐Jakob disease. Acta Neuropathol 108:295–301. [DOI] [PubMed] [Google Scholar]
  • 16. French BA, van Lewen F, Riley NE, Yuan QX, Bardag‐Gorce F, Gaal K, Lue YH, Marceau N, French SW (2001) Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin‐proteasome pathway and the frameshift mutant of ubiquitin. Exp Mol Pathol 71:241–246. [DOI] [PubMed] [Google Scholar]
  • 17. Glickman MH, Ciechanover A (2002) The ubiquitin‐proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82:373–428. [DOI] [PubMed] [Google Scholar]
  • 18. Goebel HH, Goldfarb L (2002) Desmin‐related myopathies. In: Karpati G, ed. Structural and molecular basis of skeletal muscle diseases. Basel : ISN Neuropath Press, pp:70–73. [Google Scholar]
  • 19. Goldfarb LG, Park K‐Y, Cervenáková L, Gorokhova S, Lee HS, Vasconcelos O, Nagle JW, Semino‐Mora C, Sivakumar K, Dalakas MC (1998) Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 19:402–403. [DOI] [PubMed] [Google Scholar]
  • 20. Goldfarb LG, Vicart P, Goebel HH, Dalakas MC (2004) Desmin myopathy. Brain 127:723–734. [DOI] [PubMed] [Google Scholar]
  • 21. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP (1995) Inclusion body myositis and myopathies. Ann Neurol 38:705–713. [DOI] [PubMed] [Google Scholar]
  • 22. Hoffman EP (2003) Desminopathies: good stuff lost, garbage gained, or the trashman misdirected Muscle Nerve 27:643–645. [DOI] [PubMed] [Google Scholar]
  • 23. Hohlfeld R (2002) Inclusion body myositis. In: Karpati G, ed. Structural and molecular basis of skeletal muscle diseases. Basel : ISN Neuropath Press, pp:228–230. [Google Scholar]
  • 24. Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143:1883–1898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Jones SE, Jomary C (2002) Clusterin. Int J Bio-chem Cell Biol 34:427–431. [DOI] [PubMed] [Google Scholar]
  • 26. Junn E, Lee SS, Suhr UT, Mouradian MM (2002) Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 277:47870–47877. [DOI] [PubMed] [Google Scholar]
  • 27. Kaminska A, Strelhov SU, Goudeau B Olive M, Dagvdorj A, Fidzianska A, Simon‐Casteras M, Sha‐tunov A, Dalakas MC, Ferrer I, Kwiecinski H, Vicart P, Goldfarb LG (2004) Small deletions disturb desmin architecture leading to breakdown of muscle cells and development of skeletal or cadioskeletal myopathy. Hum Genet 114:306–313. [DOI] [PubMed] [Google Scholar]
  • 28. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727–738. [DOI] [PubMed] [Google Scholar]
  • 29. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524–530. [DOI] [PubMed] [Google Scholar]
  • 30. Kostova Z, Wolf DH (2003) For whom the bell tolls: Protein quality control of the endoplasmic reticulum and the ubiquitin‐proteasome connection. EMBO J 22:2309–2317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Lidström AM, Bogdanovic N, Hesse C, Volk‐man I, Davidsson P, Blennow K (1998) Clusterin (Apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol 154:511–521. [DOI] [PubMed] [Google Scholar]
  • 32. Matsubara E, Frangione B, Ghiso J (1995) Characterization of apolipoprotein J‐Alzheimer's A beta interactions. J Biol Chem 270:7563–7567. [DOI] [PubMed] [Google Scholar]
  • 33. McGeer PL, Kawamata T, Walker DG (1992) Distribution of clusterin in Alzheimer brain tissue. Brain Res 579:337–341. [DOI] [PubMed] [Google Scholar]
  • 34. McHattie S, Wells GAH, Bee J, Edington N (1999) Clusterin in bovine spongiform encephalopathy (BSE). J Comp Path 121:159–171. [DOI] [PubMed] [Google Scholar]
  • 35. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW (2002) Aggresome‐related biogenesis of Lewy bodies. Eur JNeurosci 16:2136–2148. [DOI] [PubMed] [Google Scholar]
  • 36. Michel D, Chatealin G, North S, Brun G (1997) Stress‐induced transcription of the clusterin/apoJ gene. Biochem J 328:45–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Muñoz‐Mármol AM, Strasser G, Isamat M, Coulumbe PA, Yang Y, Roca X, Vela E, Mate JL, Coll J, Fernández‐Figueras MT, Navas Palacios JJ, Ariza A, Fuchs E (1998) A dysfunctional desmin mutation in a patient with severe generalised myopathy. Proc Natl Acad Sci U S A 95:11312–11317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Nakano S, Engel AG, Akiguchi I, Kimura J. Myofibrillar Myopathy (1997) III. Abnormal expression of cyclin‐dependent kinases and nuclear proteins. J Neuropathol Exp Neurol 56:850–856. [DOI] [PubMed] [Google Scholar]
  • 39. Nakano S, Engel AG, Waclawik AJ, Emslie‐Smith AM, Busis NA. Myofibrillar myopathy with abnormal foci of desmin positivity (1996). I. Light and electron miscroscopy analysis of 10 cases. J Neuropathol Exp Neurol 55:549–562. [DOI] [PubMed] [Google Scholar]
  • 40. Nakano S, Shinde A, Kawashima S, Nakamura S, Akiguchi, Kimura J (2001) Inclusion body myositis. Expression of extracellular signal‐regulated kinase and its substrates. Neurology 56:87–93. [DOI] [PubMed] [Google Scholar]
  • 41. Oakley BR (1995) Cell biology. A nice ring to the centrosome. Nature 378:555–556. [DOI] [PubMed] [Google Scholar]
  • 42. Olanow CW, Perl DP, DeMartino GN, McNaught KS (2004) Lewy‐body formation in aggresome‐related process: a hypothesis. Lancet Neurol 8:496–503. [DOI] [PubMed] [Google Scholar]
  • 43. Olivé M, Goldfarb L, Moreno D, Laforet E, Dagvadorj A, Sambuughin N, Martínez‐Matos JA, Martínez F, Alió J, Farrero E, Vicart P, Ferrer I (2004) Desmin‐related myopathy: clinical, electrophysiological, radiological, neuropathological, and genetic studies. J Neurol Sci 219:125–137. [DOI] [PubMed] [Google Scholar]
  • 44. Oliveira AS, Corbo M, Duigou G, Gabbai AA, Hays AP (1993) Expression of cell death marker (clusterin) in muscle target fibers. Arq Neuropsychiatr 51:371–376. [DOI] [PubMed] [Google Scholar]
  • 45. Prayson RA, Cohen ML (1997) Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis. Hum Pathol 28:887–892. [DOI] [PubMed] [Google Scholar]
  • 46. Riley NE, Li J, Worrall S, Rothnagel JA, Swagell C, van Leeuwe FW, French SW (2002) The Mallory body as an aggresome: in vitro studies. Exp Mol Pathol 72:17–23. [DOI] [PubMed] [Google Scholar]
  • 47. Rosenberg ME, Silkensen J (1995) Clusterin: physiological and pathological considerations. Int Biochem Cell Biol 27:633–645. [DOI] [PubMed] [Google Scholar]
  • 48. Ross CA, Poirier M (2004) Protein aggregation and neurodegenerative diseases. Nature Med 10: S10–S17. [DOI] [PubMed] [Google Scholar]
  • 49. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A, Robbins J (2004) Desmin‐related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 101:10132–10136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Sasaki K, Doh‐ura K, Ironside JW, Iwaki T (2002a) Increased clusterin (apolipoprotein J) expression in human and mouse brains infected with transmissible spongiform encephalopathies. Acta Neuropathol 103:199–208. [DOI] [PubMed] [Google Scholar]
  • 51. Sasaki K, Doh‐ura K, Wakisawa Y, Iwaki T (2002b) Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with _‐synucleinopathies. Acta Neuropathol 104:225–230. [DOI] [PubMed] [Google Scholar]
  • 52. Schwochan GB, Nath KA, Rosenberg ME, (1998) Clusterin protects against oxidative stress in vitro through aggregative and non‐aggregative properties. Kidney Int 53:1647–1653. [DOI] [PubMed] [Google Scholar]
  • 53. Selcen D, Engel AG (2003) Myofibrillar myopathy caused by novel dominant negative αB‐crystallin mutations. Ann Neurol 54:804–810. [DOI] [PubMed] [Google Scholar]
  • 54. Selcen D, Engel AG (2004) Mutations in myotilin cause myofibrillar myopathy. Neurology 62:1363–1371. [DOI] [PubMed] [Google Scholar]
  • 55. Selcen D, Ohno K, Engel AG (2004) Myofibrillar myopathy: clinical, morphological and genetic studies in 68 patients. Brain 127:439–451. [DOI] [PubMed] [Google Scholar]
  • 56. Serrando M, Casanovas A, Esquerda JE (2002) Occurrence of glutamate receptor subunit containing aggresome‐like structures during normal development of rat spinal cord interneurons. J Comp Neurol 442:23–34. [DOI] [PubMed] [Google Scholar]
  • 57. Shimohata T, Sato A, Burke JR, Strittmatter WJ, Tsuji S (2002) Expanded polyglutamine stretches form an “aggresome. Neurosci Lett 323:215–218. [DOI] [PubMed] [Google Scholar]
  • 58. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM (2004) Aggresomes formed by alpha‐synuclein and synphilin‐1 are cytoprotective. J Biol Chem 279:4625–4631. [DOI] [PubMed] [Google Scholar]
  • 59. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic‐Plese S, Fischbeck KH (2003) Aggresomes protect cells by enhancing the degradation of toxic polyglutamine‐containing protein. Hum Mol Genet 12:749–757. [DOI] [PubMed] [Google Scholar]
  • 60. Teckman JH, Perlmutter DH (2000) Retention of mutant α 1‐antitripsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol 279: G961–974. [DOI] [PubMed] [Google Scholar]
  • 61. Vattemi G, Engel WK, McFerrin J, Askanas V (2004) Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 164:1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Vicart P, Caron A, Guicheney P, Prevost MC, Faure A, Chateau D, Chapon F, Tome F, Dupret JM, Paulin D, Fardeau M (1998) A missense mutation in the aB‐crystallin chaperone gene causes a desmin‐related myopathy. Nat Genet 20:92–95. [DOI] [PubMed] [Google Scholar]
  • 63. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE (2001) Accumulation of mutant huntingtin fragments in aggresome‐like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12:1393–1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Wilczynski GM, Engel WK, Askanas V (2000) Association of active extracellular signal‐regulated protein kinase with paired helical filaments of inclusion‐body myositis muscle suggests its role in inclusion‐body myositis tau phosphorylation. Am J Pathol 156:1835–1840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Wojcik C, DeMartino GN (2003) Intracellular localization of proteasomes. Int J Biochem Cell Biol 35:579–589. [DOI] [PubMed] [Google Scholar]
  • 66. Zanusso G, Vattemi G, Ferrari S, Tabaton M, Pecini E, Cavallaro T, Tomelleri G, Filosto M, Tonin P, Nardelli E, Rizzuto N, Monaco S (2001) Increased expression of the normal cellular isoform of prion protein in inclusion‐body myositis, inflammatory myopathies and denervation atrophy. Brain Pathol 11:182–189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Zheng Y, Wong ML, Alberts B, Mitchinson T (1995) Nucleation of the microtubule assembly by a gamma‐tubulin‐containing ring complex. Nature 378:578–583. [DOI] [PubMed] [Google Scholar]
  • 68. Zlokovic BV (1996) Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti‐amyloidogenic role of the blood brain barrier. Life Sci 59:1483–1497. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES